What is IFRX (IFRX) stock price today?

IFRX (IFRX) is currently trading at $2.25, up 5.4% today.

What is IFRX P/E ratio?

IFRX's P/E ratio is -4.16. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IFRX return on equity (ROE)?

IFRX's return on equity (ROE) is -79.94%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is IFRX's market cap?

IFRX has a market capitalization of $330.67M.

NASDAQ · Biotechnology

IFRX (IFRX) Stock

$2.25 +5.40% NASDAQ: IFRX Healthcare

Valuation

Metric	Value
Price	$2.25
Market Cap	$330.67M
P/E Ratio	-4.16
P/B Ratio	2.62
P/S Ratio	3300.65
EPS (TTM)	$-0.64
52-Week High	$2.95
52-Week Low	$0.74
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-79.94%
ROA	-39.06%
ROCE	-117.07%
Gross Margin	-246.46%
Operating Margin	-1444.45%
Net Margin	-1463.04%
Debt/Equity	0.02
Current Ratio	4.15

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-48.0M	$-32.0M	$-45.0M	$-53.0M	$-48.0M
Net Profit	$-46.0M	$-29.0M	$-43.0M	$-46.0M	$-46.0M
EPS	$-1.10	$-0.61	$-0.78	$-0.78	$-0.66
Op Margin	—	—	-70685.6%	-31911.4%	-164525.5%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$125.0M	$102.0M	$120.0M	$76.0M	$55.0M
Total Liabilities	$20.0M	$14.0M	$18.0M	$15.0M	$14.0M
Cash	$26.0M	$16.0M	$13.0M	$18.0M	$16.0M
Borrowings	$1.0M	$1.0M	$1.0M	$1.0M	$1.0M

Latest News

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos GlobeNewswire · Jun 30, 2026 Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength? Zacks · Jun 26, 2026 What Do Analysts Say About InflaRx N.V. (IFRX)? Insider Monkey · Jun 10, 2026 Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now Insider Monkey · May 31, 2026 InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline MarketBeat · May 8, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-40.0M	$-34.0M	$-38.0M	$-49.0M	$-34.0M
Investing Cash Flow	$-26.0M	$19.0M	$-18.0M	$52.0M	$3.0M
Financing Cash Flow	$-3.0M	$0	$-3.0M	$0	$0
Net Cash Flow	$0	$-10.0M	$-3.0M	$6.0M	$0
Free Cash Flow	$-40.0M	$-34.0M	$-38.0M	$-49.0M	$-34.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-444.76
EV / EBITDA	-1.81
FCF Yield	-29.88%
Quick Ratio	4.16
Interest Coverage	—
Return 1Y	125.34%
Return 3Y	-51.57%
Return 5Y	-21.79%

Ownership

Insiders Held2.95%

Institutions Held30.29%

Institutions Float Held31.21%

Institutional Holder	Shares	Report Date
Suvretta Capital Management, LLC	7,933,910	2026-03-31
683 Capital Management LLC	3,315,000	2026-03-31
Bank of America Corporation	1,975,000	2026-03-31
Eversept Partners, LP	1,758,573	2026-03-31
Morgan Stanley	1,175,576	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ARTV	$11.11	-1.65%	-2.29	$543.34M	0.00%
ATYR	$0.49	-8.67%	-0.72	$47.61M	0.00%
CNTB	$2.35	+6.82%	-2.31	$147.97M	0.00%
CNTX	$0.36	-7.44%	-6.84	$33.14M	0.00%
IMA	$5.04	-1.18%	-1.49	$56.85M	0.00%

About IFRX

IFRX is led by CEO Niels C. Riedemann, employs 74 people, headquartered in DE, publicly traded since 2017.

IFRX stock trades at $2.25 with a market capitalization of $330.67M. The stock is valued at a price-to-earnings (P/E) ratio of -4.16, price-to-book of 2.62, price-to-sales of 3300.65. Over the past 52 weeks the stock has ranged between $0.74 and $2.95, and currently trades 23.7% below its 52-week high.

On profitability, IFRX generates a return on equity (ROE) of -79.94%, return on capital employed of -117.07%, an operating margin of -1444.45%, a net profit margin of -1463.04%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides